{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hepatic%3B+Functional+Disturbance",
    "query": {
      "condition": "Hepatic; Functional Disturbance"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 50,
    "total_pages": 5,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hepatic%3B+Functional+Disturbance&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-07-22T17:11:18.619Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02132442",
      "title": "Hepatic Dysfunction, Vitamin D Status, and Glycemic Control in Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 2 Diabetes",
        "Nonalcoholic Fatty Liver Disease",
        "Vitamin D Deficiency"
      ],
      "interventions": [
        {
          "name": "Ergocalciferol, placebo",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "University of Massachusetts, Worcester",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "10 Years to 50 Years"
      },
      "enrollment_count": 12,
      "start_date": "2014-03",
      "completion_date": "2016-10",
      "has_results": false,
      "last_update_posted_date": "2017-01-10",
      "last_synced_at": "2026-07-22T17:11:18.619Z",
      "location_count": 1,
      "location_summary": "Worcester, Massachusetts",
      "locations": [
        {
          "city": "Worcester",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02132442"
    },
    {
      "nct_id": "NCT05195125",
      "title": "Use of Direct Peritoneal Resuscitation in High-risk Liver Transplant Recipients",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "End Stage Liver DIsease",
        "Obesity",
        "Acute Kidney Injury"
      ],
      "interventions": [
        {
          "name": "Direct Peritoneal Resuscitation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2022-02-01",
      "completion_date": "2023-12",
      "has_results": false,
      "last_update_posted_date": "2023-06-08",
      "last_synced_at": "2026-07-22T17:11:18.619Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05195125"
    },
    {
      "nct_id": "NCT00047346",
      "title": "Erlotinib in Treating Patients With Unresectable Liver Cancer and Liver Dysfunction",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Adult Primary Hepatocellular Carcinoma",
        "Advanced Adult Primary Liver Cancer",
        "Localized Unresectable Adult Primary Liver Cancer",
        "Recurrent Adult Primary Liver Cancer"
      ],
      "interventions": [
        {
          "name": "erlotinib hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2002-08",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-01-23",
      "last_synced_at": "2026-07-22T17:11:18.619Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00047346"
    },
    {
      "nct_id": "NCT07358546",
      "title": "A Study of Efimosfermin Alfa in Adults With Hepatic Impairment",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-alcoholic Fatty Liver Disease"
      ],
      "interventions": [
        {
          "name": "Efimosfermin alfa",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 32,
      "start_date": "2026-03-13",
      "completion_date": "2027-10-13",
      "has_results": false,
      "last_update_posted_date": "2026-06-09",
      "last_synced_at": "2026-07-22T17:11:18.619Z",
      "location_count": 3,
      "location_summary": "Rialto, California • Tampa, Florida • San Antonio, Texas",
      "locations": [
        {
          "city": "Rialto",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07358546"
    },
    {
      "nct_id": "NCT07192159",
      "title": "Quantitative Ultrasound(DeepUSFF) vs MRI-PDFF for Liver Fat Assessment in MASLD",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Metabolic Dysfunction-Associated Steatotic Liver Disease",
        "Hepatic Steatosis",
        "Liver Disease Parenchymal"
      ],
      "interventions": [
        {
          "name": "Quantitative ultrasound (DeepUSFF)",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Seoul National University Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 62,
      "start_date": "2025-06-24",
      "completion_date": "2026-06-30",
      "has_results": false,
      "last_update_posted_date": "2025-09-25",
      "last_synced_at": "2026-07-22T17:11:18.619Z",
      "location_count": 1,
      "location_summary": "Boardman, Ohio",
      "locations": [
        {
          "city": "Boardman",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07192159"
    },
    {
      "nct_id": "NCT00499811",
      "title": "Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Adult Grade III Lymphomatoid Granulomatosis",
        "Adult Nasal Type Extranodal NK/T-cell Lymphoma",
        "Anaplastic Large Cell Lymphoma",
        "Angioimmunoblastic T-cell Lymphoma",
        "Cutaneous B-cell Non-Hodgkin Lymphoma",
        "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue",
        "Intraocular Lymphoma",
        "Nodal Marginal Zone B-cell Lymphoma",
        "Primary Central Nervous System Hodgkin Lymphoma",
        "Primary Central Nervous System Non-Hodgkin Lymphoma",
        "Recurrent Adult Burkitt Lymphoma",
        "Recurrent Adult Diffuse Large Cell Lymphoma",
        "Recurrent Adult Diffuse Mixed Cell Lymphoma",
        "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma",
        "Recurrent Adult Grade III Lymphomatoid Granulomatosis",
        "Recurrent Adult Hodgkin Lymphoma",
        "Recurrent Adult Immunoblastic Large Cell Lymphoma",
        "Recurrent Adult Lymphoblastic Lymphoma",
        "Recurrent Adult T-cell Leukemia/Lymphoma",
        "Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma",
        "Recurrent Grade 1 Follicular Lymphoma",
        "Recurrent Grade 2 Follicular Lymphoma",
        "Recurrent Grade 3 Follicular Lymphoma",
        "Recurrent Mantle Cell Lymphoma",
        "Recurrent Marginal Zone Lymphoma",
        "Recurrent Mycosis Fungoides/Sezary Syndrome",
        "Recurrent Small Lymphocytic Lymphoma",
        "Small Intestine Lymphoma",
        "Splenic Marginal Zone Lymphoma",
        "Stage III Adult Burkitt Lymphoma",
        "Stage III Adult Diffuse Large Cell Lymphoma",
        "Stage III Adult Diffuse Mixed Cell Lymphoma",
        "Stage III Adult Diffuse Small Cleaved Cell Lymphoma",
        "Stage III Adult Hodgkin Lymphoma",
        "Stage III Adult Immunoblastic Large Cell Lymphoma",
        "Stage III Adult Lymphoblastic Lymphoma",
        "Stage III Adult T-cell Leukemia/Lymphoma",
        "Stage III Cutaneous T-cell Non-Hodgkin Lymphoma",
        "Stage III Grade 1 Follicular Lymphoma",
        "Stage III Grade 2 Follicular Lymphoma",
        "Stage III Grade 3 Follicular Lymphoma",
        "Stage III Mantle Cell Lymphoma",
        "Stage III Marginal Zone Lymphoma",
        "Stage III Mycosis Fungoides/Sezary Syndrome",
        "Stage III Small Lymphocytic Lymphoma",
        "Stage IV Adult Burkitt Lymphoma",
        "Stage IV Adult Diffuse Large Cell Lymphoma",
        "Stage IV Adult Diffuse Mixed Cell Lymphoma",
        "Stage IV Adult Diffuse Small Cleaved Cell Lymphoma",
        "Stage IV Adult Hodgkin Lymphoma",
        "Stage IV Adult Immunoblastic Large Cell Lymphoma",
        "Stage IV Adult Lymphoblastic Lymphoma",
        "Stage IV Adult T-cell Leukemia/Lymphoma",
        "Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma",
        "Stage IV Grade 1 Follicular Lymphoma",
        "Stage IV Grade 2 Follicular Lymphoma",
        "Stage IV Grade 3 Follicular Lymphoma",
        "Stage IV Mantle Cell Lymphoma",
        "Stage IV Marginal Zone Lymphoma",
        "Stage IV Mycosis Fungoides/Sezary Syndrome",
        "Stage IV Small Lymphocytic Lymphoma",
        "Unspecified Adult Solid Tumor, Protocol Specific",
        "Waldenström Macroglobulinemia"
      ],
      "interventions": [
        {
          "name": "vorinostat",
          "type": "DRUG"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2007-06",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2014-02-24",
      "last_synced_at": "2026-07-22T17:11:18.619Z",
      "location_count": 11,
      "location_summary": "Duarte, California • Los Angeles, California • Atlanta, Georgia + 8 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00499811"
    },
    {
      "nct_id": "NCT01392807",
      "title": "Open-label Study to Assess the Pharmacokinetics of NKTR-118 in Patients With Impaired Hepatic Function",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hepatic; Functional Disturbance"
      ],
      "interventions": [
        {
          "name": "NKTR-118",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2011-07",
      "completion_date": "2011-11",
      "has_results": false,
      "last_update_posted_date": "2014-10-15",
      "last_synced_at": "2026-07-22T17:11:18.619Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01392807"
    },
    {
      "nct_id": "NCT01366144",
      "title": "Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Carcinoma",
        "Carcinoma of Unknown Primary",
        "Endometrial Carcinoma",
        "Esophageal Carcinoma",
        "Liver Failure",
        "Lung Carcinoma",
        "Malignant Head and Neck Neoplasm",
        "Malignant Testicular Neoplasm",
        "Melanoma",
        "Metastatic Malignant Solid Neoplasm",
        "Ovarian Carcinoma",
        "Renal Failure",
        "Unresectable Malignant Neoplasm",
        "Urothelial Carcinoma"
      ],
      "interventions": [
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "Veliparib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 94,
      "start_date": "2011-06-20",
      "completion_date": "2027-03-03",
      "has_results": false,
      "last_update_posted_date": "2026-06-17",
      "last_synced_at": "2026-07-22T17:11:18.619Z",
      "location_count": 17,
      "location_summary": "Duarte, California • Sacramento, California • South Pasadena, California + 13 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "South Pasadena",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01366144"
    },
    {
      "nct_id": "NCT05987124",
      "title": "Defibrotide Dose-escalation for SOS Post-HSCT",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Sinusoidal Obstruction Syndrome",
        "Veno-occlusive Disease"
      ],
      "interventions": [
        {
          "name": "Defibrotide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "New York Medical College",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Month",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "1 Month to 75 Years"
      },
      "enrollment_count": 20,
      "start_date": "2024-03-20",
      "completion_date": "2028-08-01",
      "has_results": false,
      "last_update_posted_date": "2026-04-15",
      "last_synced_at": "2026-07-22T17:11:18.619Z",
      "location_count": 1,
      "location_summary": "Vallhala, New York",
      "locations": [
        {
          "city": "Vallhala",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05987124"
    },
    {
      "nct_id": "NCT05224609",
      "title": "A Study to Learn About the Study Medicine (Called Lorlatinib) in People With Liver Dysfunction",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Moderate Hepatic Impairment",
        "Severe Hepatic Impairment",
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Lorlatinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 21,
      "start_date": "2022-04-28",
      "completion_date": "2024-08-13",
      "has_results": false,
      "last_update_posted_date": "2024-08-30",
      "last_synced_at": "2026-07-22T17:11:18.619Z",
      "location_count": 3,
      "location_summary": "Tustin, California • Tampa, Florida • Saint Paul, Minnesota",
      "locations": [
        {
          "city": "Tustin",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Saint Paul",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05224609"
    }
  ]
}